Founded in 2011 and now trading as part of the Easton Biopharmaceuticals group (listed on the Shanghai STAR Market, stock code 688513, since 2020), Sichuan Qingmu Pharmaceutical manufactures specialty and oncology APIs including cabozantinib malate, darolutamide, fruquintinib, lurbinectedin, axitinib, ixazomib citrate, omadacycline tosylate, and gadobutrol. Recognized as a National High-tech Enterprise, the company holds 82 domestic and international patents (15 internationally granted) including the first CEP for bisoprolol fumarate obtained in 2017, invests roughly 16% of annual sales in R&D with a team where over 41% hold PhD or master's degrees, and offers CMO and CDMO contract manufacturing with buyer-specified customization and small-order acceptance to global markets.
No comments available.
Leave your rating & comment